Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Connect Biopharma Holdings (CNTB) EBITDA Margin (2024 - 2025)

Connect Biopharma Holdings' EBITDA Margin history spans 2 years, with the latest figure at 106887.5% for Q3 2025.

  • For Q3 2025, EBITDA Margin fell 10587798.0% year-over-year to 106887.5%; the TTM value through Sep 2025 reached 6998.88%, changed N/A, while the annual FY2024 figure was 62.56%, N/A changed from the prior year.
  • EBITDA Margin for Q3 2025 was 106887.5% at Connect Biopharma Holdings, down from 1431.23% in the prior quarter.
  • Across five years, EBITDA Margin topped out at 1009.52% in Q3 2024 and bottomed at 106887.5% in Q3 2025.